Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
129 hedge funds and large institutions have $545M invested in Array Biopharma Inc in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 41 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6% more funds holding
Funds holding: 122 → 129 (+7)
2% more capital invested
Capital invested by funds: $533M → $545M (+$11.8M)
12% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 41
60% less call options, than puts
Call options by funds: $1.42M | Put options by funds: $3.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$25.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$13.2M |
| 3 |
AC
Apex Capital
Orinda,
California
|
+$4.96M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.4M |
| 5 |
CNB
City National Bank
Beverly Hills,
Delaware
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.73M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.22M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.1M |
| 4 |
TA
Teachers Advisors
New York
|
-$2.65M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.5M |
ARRY Hedge Fund Activity: Q2 2014 in Review
129 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2014, worth a combined $545M — up 2.2% from $533M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ARRY positions and 12 closed out — a net gain of 8 holders — while 36 added to existing stakes and 41 trimmed.
The largest buyer was BVF Inc, adding an estimated $25.8M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $9.73M sold.
- 129 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2014, up from 122 in Q1 2014.
- Funds reported $545M of Array Biopharma Inc stock for Q2 2014, up 2.2% quarter-over-quarter.
- 20 funds opened new Array Biopharma Inc positions in Q2 2014 and 12 closed out, a net change of +8 holders.
- The largest Array Biopharma Inc buyer in Q2 2014 was BVF Inc, an estimated $25.8M added.
- The largest Array Biopharma Inc seller in Q2 2014 was Balyasny Asset Management, an estimated $9.73M sold.
Based on aggregated 13F filings for Q2 2014.